News & Updates

Severe outcomes more likely with Omicron XBB.1.16 in SG

29 Dec 2023 by

In a preliminary analysis, the risk of severe outcomes was higher in individuals infected with the Omicron XBB.1.16 subvariant compared with those who were infected with other subvariants such as the XBB.1.5 or XBB.1.9.

Severe outcomes more likely with Omicron XBB.1.16 in SG

29 Dec 2023

$ESMO 2023: Sotorasib + panitumumab prolongs PFS in chemorefractory KRASG12C-mutated mCRC$

ESMO 2023: Sotorasib + panitumumab prolongs PFS in chemorefractory KRASG12C-mutated mCRC

29 Dec 2023 by

Dual blockade of KRAS^G12C and EGFR may overcome treatment resistance in KRAS^G12C-mutated colorectal cancer (CRC). At the European Society for Medical Oncology Congress 2023 (ESMO 2023), Dr Filippo Pietrantonio of the Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, presented primary results of the phase III CodeBreaK 300 trial, which demonstrated significantly prolonged progression-free survival (PFS) with sotorasib in combination with panitumumab vs standard care with trifluridine plus tipiracil (T/T) or regorafenib in patients with chemorefractory metastatic CRC (mCRC) harbouring a KRAS^G12C mutation. Discussant Professor Miriam Koopman of Department of Medical Oncology, Utrecht University, Utrecht, Netherlands, shared her insights into the trial.

ESMO 2023: Sotorasib + panitumumab prolongs PFS in chemorefractory KRASG12C-mutated mCRC

29 Dec 2023

Sunvozertinib shows promise in pretreated NSCLC with EGFR exon 20 insertions

29 Dec 2023

The oral selective tyrosine kinase inhibitor sunvozertinib demonstrates therapeutic potential in patients with nonsmall cell lung cancer (NSCLC) with EGFR exon 20 insertions (exon20ins) who have previously received platinum-based chemotherapy, according to the results of a phase II WU-KONG6 study.

Sunvozertinib shows promise in pretreated NSCLC with EGFR exon 20 insertions

29 Dec 2023

Novel probiotics may improve mood disorder symptoms and sleep quality

29 Dec 2023 by

A novel multi-strain E3 probiotic formulation improves symptoms of depression and anxiety as well as sleep quality, a prospective cohort study has shown.

Novel probiotics may improve mood disorder symptoms and sleep quality

29 Dec 2023

Upadacitinib induces CD remission in patients with prior surgery

28 Dec 2023 by

Treatment with upadacitinib (UPA) delivers clinical benefits to patients with prior Crohn’s disease (CD)-related surgeries, according to a study presented at AIBD 2023. Moreover, a maintenance dose of 30 mg once a day (QD) demonstrates greater efficacy.

Upadacitinib induces CD remission in patients with prior surgery

28 Dec 2023

Marstacimab trumps FRT for severe haemophilia without inhibitors

28 Dec 2023 by

The novel, investigational anti-tissue factor pathway inhibitor marstacimab outdid factor replacement therapy (FRT) in reducing bleeds in patients with severe haemophilia A (HA) or moderately severe to severe haemophilia B (HB) without inhibitors beyond 12 months in the phase III BASIS trial.

Marstacimab trumps FRT for severe haemophilia without inhibitors

28 Dec 2023

Risankizumab superior to ustekinumab in severe CD

27 Dec 2023 by

Risankizumab outdoes ustekinumab in achieving endoscopic remission at week 24 in patients with moderate-to-severe Crohn’s disease (CD), as well as in other clinical, endoscopic, and quality of life (QoL) outcomes, as shown by the results of the phase IIIB SEQUENCE trial presented at AIBD 2023.

Risankizumab superior to ustekinumab in severe CD

27 Dec 2023

Shifting to a plant-based diet may be key to better cardiometabolic health

27 Dec 2023 by

A systematic review and meta-analysis of prospective studies demonstrate that switching from animal-based (AB) to plant-based (PB) foods conferred cardiometabolic improvements.